Suppression of tumorigenicity 8 (ovarian)

Suppression of tumorigenicity 8 (ovarian) is a protein that in humans is encoded by the ST8 gene. This gene is located to a 300-kb segment of chromosome 6q25-27, which facilitate further efforts to identify a gene associted with ovarian cancer.The official Symbol (ST8) and the Official name Suppression of tumorigenicity 8 are maintained by the HGNC. Also known as Oncogene OVC(ovarian adenocarcinoma oncogene).The inactivation of tumor suppressor gene in ST8 gene may be crucial for the development of cancer. We examine the homologous regions in humans- the short arm of chromosome 6 for deletions in sporadic ovarian adenocarcinomas.In 91 informative sporadic tumors,34 losses their heterozygosity including some benign, low-malignant-potential and early stage tumors,suggesting that it is an early event in the development of ovarian adenocarcinoma. In different portions of chromosome 6q there were deletions and translocations which were subsequently reported by cytogenic analyses of primary ovarian carcinomas and ovarian cancer cell lines. Patients with advanced disease who achieved a complete remission documented by peritoneoscopy or laparotomy (or both) have a median survival that will exceed three years.People with ovarian adenocarcinoma were treated with four drug combination- hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil — with the oral alkylating agent, melphalan. Four drug combination helped in the increased overall rate in the treatment but was more toxigenic than melphalan.The four-drug regimen is more effective than melphalan in the management of advanced ovarian adenocarcinoma.